Completed PHASE3 INTERVENTIONAL 2-arm NCT00311363

Long-Term Study of Gabapentin Enacarbil (GEn, XP13512) vs. Placebo in Patients With Restless Legs Syndrome.

A Long-Term Study of XP13512 Versus Placebo Treatment Assessing Maintenance of Efficacy and Safety in Patients With Restless Legs Syndrome.

Sponsor: XenoPort, Inc.

Conditions Restless Legs Syndrome

Interventions GEn (XP13512) Placebo

Updated 6 times since 2017 Last updated: Jul 15, 2013 Started: Apr 30, 2006 Primary completion: Nov 30, 2007 Completion: Nov 30, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00311363, this PHASE3 trial focuses on Restless Legs Syndrome and remains completed. Sponsored by XenoPort, Inc., it has been updated 6 times since 2006, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Apr 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

XenoPort, Inc.

Data source: XenoPort, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.